The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-Calanolide A

Molecular Pharmacology

Volumn 68, Issue 3, 2005, Pages 652-659

  Auwerx, Joeri ^a   Rodríguez Barrios, Fátima ^b   Ceccherini Silberstein, Francesca ^c   San Félix, Ana ^d   Velázquez, Sonsoles ^d   De Clercq, Erik ^a   Camarasa, María José ^d   Perno, Carlo Federico ^c   Gago, Federico ^b   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALANOLIDE A; DELAVIRDINE; EFAVIRENZ; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE;

AMINO ACID ANALYSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL;

COUMARINS; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PYRANOCOUMARINS; REVERSE TRANSCRIPTASE INHIBITORS; THREONINE;

EID: 24044513654     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.012351     Document Type: Article

References (38)

1. Auwerx J, Esnouf R, De Clercq E, and Balzarini J (2004) Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol Pharmacol 65:244-251.
2. Auwerx J, Van Nieuwenhove J, Rodríguez-Barrios F, de Castro S, Velázquez S, Ceccherini-Silberstein F, De Clercq E, Camarasa MJ, Perno CF, Gago F, et al. (2005) The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. FEBS Lett 579:2294-2300.
3. Balzarini J (1999) Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol 58:1-27.
4. Balzarini J (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 4:921-944.
5. Balzarini J, Auwerx J, Rodríguez-Barrios F, Chedad A, Ceccherini-Silberstein A, García-Aparicio C, Velázquez S, De Clercq E, Perno CF, Camarasa MJ, et al. (2005) The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. Mol Pharmacol 68:49-60.
6. Balzarini J, Karlsson A, Vandamme A-M, Péréz- Péréz M-J, Zhang H, Vrang L, Ö berg B, Backbro K, Unge T, San-Félix A, et al. (1993a) Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′- bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino- 1″,2″-oxathiole-2″,2″-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sc USA 90:6952-6956.
7. Balzarini J, Pelemans H, Esnouf R, and De Clercq E (1998) A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res Hum Retroviruses 14:255-260.
8. Balzarini J, Péréz-Péréz MJ, San-Felix A, Camarasa MJ, Bathurst IC, Barr PJ, and De Clercq E (1992) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T). J Biol Chem 267:11831-11838.
9. Balzarini J, Velázquez S, San-Félix A, Karlsson A, Péréz-Péréz MJ, Camarasa MJ, and De Clercq E (1993b) Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues. Mol Pharmacol 43:109-114.
10. Boyer PL, Ding J, Arnold E, and Hughes SH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38:1909-1914.
11. Buckheit RW Jr, Fliakas-Boltz V, Decker WD, Roberson JL, Stup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR, et al. (1995) Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res 26:117-132.
12. Buckheit RW Jr, White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A, and Bader JP (1999) Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide and dihydrocostatolide. Antimicrob Agents Chemother 43:1827-1834.
13. Camarasa MJ, San-Félix A, Velázquez S, Péréz- Péréz MJ, Gago F, and Balzarini J (2004) TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr Top Med Chem 4:945-963.
14. Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, D'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, et al. (2005) High sequence conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. J Virol, in press.
15. Currens MJ, Gulakowski RJ, Mariner JM, Moran RA, Buckheit RW Jr, Gustafson KR, McMahon JB, and Boyd MR (1996a) Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 279:645-651.
16. Currens MJ, Mariner JM, McMahon JB, Boyd MR, Shulman N, and Winters M (1996b) Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A. J Pharmacol Exp Ther 279:652-661.
17. D'Aquila RT and Summers WC (1989) HIV-1 reverse transcriptase/ ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction. J Acquir Immune Defic Syndr 2:579-587.
18. De Clercq E (1999) Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco 54:26-45.
19. DeLano WL (2004) The PyMOL Molecular Graphics System. DeLano Scientific LLC, San Carlos, CA.
20. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, and Stuart DI (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA 94:3984-3989.
21. Huang H, Chopra R, Verdine GL, and Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science (Wash DC) 282:1669-1675.
22. Jonckheere H, De Vreese K, Debyser Z, Vandekerckhove J, Balzarini J, Desmyter J, De Clercq E, and Anné J (1996) A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1. J Virol Methods 61:113-125.
23. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH II, McMahon JB, Currens MJ, Buckheit RW Jr, Hughes SH, Cragg GM, and Boyd MR (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 35:2735-2743.
24. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, and Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (Wash DC) 256:1783-1790.
25. Pandey PK, Kaushik N, Singh K, Sharma B, Upadhyay AK, Kumar S, Harris D and Pandey VN (2002) Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem 3:18.
26. Pandey PK, Kaushik N, Talele TT, Yadav PN, and Pandey VN (2001) The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40:9505-9512.
27. Pelemans H, Aertsen A, Van Laethem K, Vandamme A-M, De Clercq E, Péréz-Péréz M-J, San-Félix A, Velázquez S, Camarasa M-J, and Balzarini J (2001) Sitedirected mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 280:97-106.
28. Pelemans H, Esnouf RM, Jonckheere H, De Clercq E, and Balzarini J (1998) Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J Biol Chem 273:34234-34239.
29. Pérez-Pérez M-J, San-Félix A, Balzarini J, De Clercq E, and Camarasa M-J (1992) TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)- beta-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole 2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J Med Chem 35:2988-2995.
30. Quan Y, Motakis D, Buckheit R Jr, Xu ZQ, Flavin MT, Parniak MA, and Wainberg MA (1999) Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antivir Ther 4:203-209.
31. Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, and Stammers DK (2004) Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J Mol Biol 336:569-578.
32. Rodríguez-Barrios F, Pérez C, Lobaton E, Velázquez S, Chamorro C, San-Félix A, Pérez-Pérez M-J, Camarasa M-J, Pelemans H, Balzarini J, and Gago F (2001) Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p55 interface of HIV-1 reverse transcriptase. J Med Chem 44:1853-1865.
33. Sluis-Cremer N, Arion D, and Parniak MA (2002) Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 62:398-405.
34. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa M-J, and Parniak MA (2000) Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″-dioxo-1″, 2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39:1427-1433.
35. Tachedjian G and Goff SP (2003) The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr Opin Investig Drugs 4:966-973.
36. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, and Goff SP (2001) Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 98:7188-7193.
37. Vandamme A-M, Van Laethem K, Van Vaerenbergh K, and De Clercq E (1998) Anti-HIV virus combination therapy and resistance management. Int Antiviral News 6:182-187.
38. Yu D, Suzuki M, Xie L, Morris-Natschke SL, and Lee KH (2003) Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 23:322-345.